Testing cerebrolysin for bleeding stroke within 6 hours
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests a drug called Cerebrolysin, which may help protect the brain after a bleeding stroke. It is given within 6 hours of the stroke, and researchers will check if it is safe and helps improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your family member must be between 18 and 80 years old.
- The stroke must have started less than 6 hours before the study begins.
- A brain scan must show bleeding in the outer part of the brain (called lobar hemorrhage), and the bleeding size must be moderate (about 30 to 80 mL).
- The stroke must be severe enough (NIHSS score of 8 or more) and cause reduced consciousness (GCS score between 5 and 12).
- Before this stroke, you should have been independent in daily activities (able to take care of yourself).
- You cannot have had a previous stroke or have certain causes of bleeding like a brain aneurysm, tumor, or head injury.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether Cerebrolysin can improve recovery in people who remain in a vegetative or minimally conscious state more than 4 weeks after a bleeding stroke. It also tracks safety, to make sure the treatment is not causing harmful side effects.
This trial tests a minimally invasive surgery to remove blood from the brain in people who had a bleeding stroke. It aims to see if doing this quickly can help patients recover better.
This trial tests whether a drug called Recombinant Factor VIIa (rFVIIa) can safely help stop bleeding in the brain during a hemorrhagic stroke. The goal is to give the drug as quickly as possible, within 2 hours of stroke onset, to see if it improves outcomes.
This trial looks at whether starting brain surgery within 8 hours after a type of stroke called intracerebral hemorrhage (bleeding in the brain) can improve outcomes. It’s for adults with a certain amount and location of bleeding and without common causes like an aneurysm or malformation.
This trial tests whether removing a certain type of brain bleed (intracerebral hemorrhage) very early, using a minimally invasive surgery approach, improves outcomes compared with standard treatment. It may help people whose bleed is large enough and who can have surgery within a strict time window.
This trial tests whether Cerebrolysin (a medication given through an IV) can help improve recovery after a stroke when given after a successful clot-removal procedure that happened several hours after the stroke began. It is being tested in people who had a large-vessel stroke in the front of the brain and meets certain imaging criteria. The goal is to see if the drug can reduce disability and improve recovery.
Hear when a new Intracerebral Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.